David Watkins

5.4k total citations
81 papers, 1.4k citations indexed

About

David Watkins is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, David Watkins has authored 81 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 27 papers in Surgery. Recurrent topics in David Watkins's work include Colorectal Cancer Treatments and Studies (31 papers), Gastric Cancer Management and Outcomes (29 papers) and Esophageal Cancer Research and Treatment (16 papers). David Watkins is often cited by papers focused on Colorectal Cancer Treatments and Studies (31 papers), Gastric Cancer Management and Outcomes (29 papers) and Esophageal Cancer Research and Treatment (16 papers). David Watkins collaborates with scholars based in United Kingdom, United States and Spain. David Watkins's co-authors include David Cunningham, Ian Chau, Sheela Rao, Naureen Starling, Clare Peckitt, Sing Yu Moorcraft, Francesco Sclafani, Cheryl Marriott, Marco Gerlinger and Geoffrey Chong and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

David Watkins

78 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Watkins United Kingdom	22	747	446	322	289	254	81	1.4k
Eun‐Kee Song South Korea	22	623 0.8×	380 0.9×	245 0.8×	277 1.0×	120 0.5×	80	1.4k
Gun Min Kim South Korea	18	785 1.1×	549 1.2×	260 0.8×	221 0.8×	351 1.4×	91	1.3k
Jacob J. Adashek United States	24	816 1.1×	506 1.1×	338 1.0×	195 0.7×	416 1.6×	106	1.5k
Abdurrahman Işıkdoğan Türkiye	19	537 0.7×	424 1.0×	204 0.6×	204 0.7×	186 0.7×	146	1.2k
Melanie Mackean United Kingdom	20	873 1.2×	469 1.1×	563 1.7×	236 0.8×	301 1.2×	48	1.7k
María José Bento Portugal	20	979 1.3×	599 1.3×	427 1.3×	447 1.5×	326 1.3×	79	1.8k
Beodeul Kang South Korea	21	756 1.0×	373 0.8×	147 0.5×	322 1.1×	143 0.6×	99	1.4k
Carmen Guillén‐Ponce Spain	24	1.0k 1.3×	434 1.0×	384 1.2×	207 0.7×	463 1.8×	133	1.9k
Emmanuel Gabriel United States	23	958 1.3×	525 1.2×	352 1.1×	850 2.9×	243 1.0×	121	1.9k
James Biagi Canada	22	1.2k 1.6×	494 1.1×	346 1.1×	503 1.7×	217 0.9×	61	1.9k

Countries citing papers authored by David Watkins

Since Specialization

Citations

This map shows the geographic impact of David Watkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Watkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Watkins more than expected).

Fields of papers citing papers by David Watkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Watkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Watkins. The network helps show where David Watkins may publish in the future.

Co-authorship network of co-authors of David Watkins

This figure shows the co-authorship network connecting the top 25 collaborators of David Watkins. A scholar is included among the top collaborators of David Watkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Watkins. David Watkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gonzalez-Exposito, Reyes, Li Su, Mónica Hernández, et al.. (2023). Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre. BMC Cancer. 23(1). 380–380. 14 indexed citations

Woolston, Andrew, Louise J. Barber, B Griffiths, et al.. (2021). Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. Nature Ecology & Evolution. 5(7). 1024–1032. 24 indexed citations

Andreyev, Jervoise, Amyn Lalji, Kabir Mohammed, et al.. (2020). The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. Supportive Care in Cancer. 29(3). 1443–1453. 13 indexed citations

Kundranda, Madappa N., Antonio Cubillo Gracián, Syed F. Zafar, et al.. (2020). Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Annals of Oncology. 31(1). 79–87. 42 indexed citations

Newey, Alice, B Griffiths, Justine Michaux, et al.. (2019). Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. Journal for ImmunoTherapy of Cancer. 7(1). 309–309. 91 indexed citations

Khan, Khurum, Nicola Valeri, Sheela Rao, et al.. (2019). Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical Reviews in Oncology/Hematology. 143. 153–163. 58 indexed citations

Khan, Khurum, Jayant K. Rane, David Cunningham, et al.. (2018). Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical Colorectal Cancer. 18(1). 64–71.e1. 11 indexed citations

Khakoo, Shelize, Nicola Valeri, Thomas R. Jones, et al.. (2018). Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer. Annals of Oncology. 29. viii661–viii661. 1 indexed citations

Fotiadis, Nicos, Naureen Starling, Ian Chau, et al.. (2018). Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases.. Journal of Clinical Oncology. 36(4_suppl). 401–401. 4 indexed citations

10.

Fontana, Elisa, Chanthirika Ragulan, David Cunningham, et al.. (2017). Multiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles. Annals of Oncology. 28. v194–v194. 1 indexed citations

11.

Moorcraft, Sing Yu, Elisa Fontana, David Cunningham, et al.. (2016). Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer. 16(1). 112–112. 14 indexed citations

12.

Denlinger, Crystal S., María Maqueda, David Watkins, et al.. (2016). Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).. Journal of Clinical Oncology. 34(15_suppl). 4043–4043. 21 indexed citations

13.

Khan, Khurum, David Cunningham, Clare Peckitt, et al.. (2016). miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget. 7(11). 12672–12681. 35 indexed citations

14.

Sclafani, Francesco, Tae‐Yop Kim, David Cunningham, et al.. (2015). A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer. JNCI Journal of the National Cancer Institute. 107(12). djv258–djv258. 73 indexed citations

15.

Watkins, David, Naureen Starling, David Cunningham, et al.. (2014). The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. European Journal of Cancer. 50(8). 1422–1429. 23 indexed citations

16.

Denlinger, Crystal S., Sun Jin Sym, Johanna C. Bendell, et al.. (2014). Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.. Journal of Clinical Oncology. 32(15_suppl). TPS4148–TPS4148. 6 indexed citations

17.

Watkins, David & David Cunningham. (2007). The Role of Epidermal Growth Factor Receptor–Targeted Antibody Therapy in Previously Treated Colorectal Cancer. Clinical Colorectal Cancer. 6. S47–S52. 1 indexed citations

18.

Arkenau, Hendrik‐Tobias, Geoffrey Chong, David Cunningham, et al.. (2006). The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Annals of Oncology. 18(3). 541–545. 63 indexed citations

19.

Rao, Sheela, David Watkins, David Cunningham, et al.. (2004). Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Annals of Oncology. 15(9). 1413–1418. 37 indexed citations

20.

Chau, Ian, David Watkins, & David Cunningham. (2002). Gemcitabine and Its Combinations in the Treatment of Malignant Lymphoma. Clinical Lymphoma. 3(2). 97–104. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact